BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dexamethasone readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dexamethasone\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05560399-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT05560399)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: A Study of Iberdomide (CC-220)
  in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory 
 Multiple Myeloma\nEstimated primary completion: November 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05560399
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04973605-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT04973605)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Phase 1b/2 Study of Sonrot
 oclax (BGB-11417) as Monotherapy and in Various Combinations With Dexameth
 asone Plus Carfilzomib\, Dexamethasone Plus Daratumumab\, and Dexamethason
 e Plus Pomalidomide in Multiple Myeloma\nEstimated primary completion: Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexametha
 sone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04973605
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06505369-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06505369)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Bispecific T-cell Redirectors 
 as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Pa
 tients\nEstimated primary completion: November 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06505369
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07537699-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07537699)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Auricular Point Stimulation Pl
 us Dexamethasone for Nausea and Vomiting Caused by Docetaxel Plus Cyclopho
 sphamide\nEstimated primary completion: November 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07537699
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07537673-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07537673)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Auricular Point Stimulation Pl
 us Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan\
 nEstimated primary completion: November 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07537673
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07537660-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07537660)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Auricular Point Stimulation Pl
 us Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclit
 axel\nEstimated primary completion: November 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07537660
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517017-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06517017)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Use of Isatuximab\, Dexamethas
 one and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Mu
 ltiple Myeloma\nEstimated primary completion: November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06517017
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05688475-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT05688475)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: A Rollover Study of CC-122\nEs
 timated primary completion: 30 November 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05688475
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study to Determine the Rec
 ommended Dose and Regimen and to Evaluate the Safety and Preliminary Effic
 acy of CC-92480 in Combination With Standard Treatments in Participants Wi
 th Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Mult
 iple Myeloma (NDMM)\nEstimated primary completion: 30 November 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03989414
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07208799-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07208799)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Comparison of Submucosal Dexam
 ethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis 
 Fractures\nEstimated primary completion: 30 November 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07208799
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03020030-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03020030)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Treatment of Newly Diagnosed A
 cute Lymphoblastic Leukemia in Children and Adolescents\nEstimated primary
  completion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03020030
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997419-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase na readout est. (NCT06997419)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Dexamethasone Palmitate for P
 ONV After Open Surgery\nEstimated primary completion: 30 November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06997419
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04546126-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT04546126)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Positron Emission Tomography (
 PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-5
 9 in Normal Human Subjects (Groups 2\, 3 & 4)\nEstimated primary completio
 n: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dex
 amethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04546126
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01562405-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT01562405)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Sotatercept (ACE-011) With Len
 alidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multipl
 e Myeloma\nEstimated primary completion: December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT01562405
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930690-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06930690)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Dexamethasone for Ureteral S
 Tent Symptoms (DUSTS)\nEstimated primary completion: December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06930690
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06342466-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06342466)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Bortezomib\, Pomalidomide\, De
 xamethasone for Systemic AL Amyloidosis\nEstimated primary completion: Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexametha
 sone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06342466
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06222723-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06222723)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: LAssa Fever Adjunct Treatment 
 With DEXamethasone\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06222723
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000617-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07000617)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Phase II Study of Dexamethas
 one\, Azacitidine\, Pegaspargase and Tislelizumab Plus Radiotherapy for Pa
 tients With Stage I/II Extranodal NK/T-cell Lymphoma\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07000617
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04009109-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04009109)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Study of Lenalidomide/Ixazomib
 /Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Di
 agnosed MM\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04009109
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02718833-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT02718833)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of Elotuzumab With Pom
 alidomide\, Bortezomib\, and Dexamethasone in Relapsed Multiple Myeloma\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT02718833
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04442022-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT04442022)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: A Study of Rituximab-Gemcita
 bine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients 
 With Relapsed/Refractory Diffuse Large B-cell Lymphoma\nEstimated primary 
 completion: December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04442022
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04182997-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT04182997)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Subjective Intraoperative Use 
 of Epidural Steroid Administration Following Discectomy\nEstimated primary
  completion: December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04182997
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228052-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07228052)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Giving Asthmatics Intramuscula
 r Steroids for Preventing Return to the Emergency Department\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07228052
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699315-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07699315)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Preoperative Dexamethasone Inj
 ection to Improve Local Anesthesia Success in Endodontic Treatment\nEstima
 ted primary completion: December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07699315
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795281-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07795281)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Intravenous Dexamethasone Adde
 d to Dexmedetomidine After Superior Trunk Block\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 examethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07795281
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999070-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase na readout est. (NCT06999070)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: The Effect of Different Doses
  of Dexamethasone on Post Spinal Anesthesia Shivering\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06999070
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04209218-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase na readout est. (NCT04209218)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Intraoperative Blood Pressure
  Management and Dexamethasone in Lung Cancer Surgery\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04209218
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609836-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase na readout est. (NCT07609836)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Caudal Dexamethasone - Bupiva
 caine in Neonates\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07609836
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07380139-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07380139)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Dexamethasone vs Dexmedetomidi
 ne in Sphenopalatine Ganglion Block for Rhinoplasty Pain\nEstimated primar
 y completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07380139
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06559553-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06559553)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: "Selinexor+Pegaspargase+Dexa
 methasone"in Ⅰ/Ⅱ NKTCL\nEstimated primary completion: 1 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06559553
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207123-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06207123)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study to Investigate LP-11
 8\, Ponatinib\, Vincristine and Dexamethasone in Relapsed/Refractory Acute
  Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06207123
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06387121-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06387121)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Efficacy and Safety of Low-dos
 e Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-A
 LL\nEstimated primary completion: 1 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06387121
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05979363-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05979363)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of Bortezomib\, Lenali
 domide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therap
 y in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia\nEst
 imated primary completion: 1 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05979363
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06704139-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT06704139)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Role of Prophylactic Antiemeti
 cs in Women Receiving Intrathecal Morphine and Lipophilic Opioids Added to
  Bupivacaine for Cesarean Section\nEstimated primary completion: 1 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 04139
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07077850-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dexamethasone: Phase na readout est. (NCT07077850)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Effect of IV Dexamethasone on
  Post-op Urinary Retention After Spinal Anesthesia\nEstimated primary comp
 letion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07077850
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324499-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dexamethasone: Phase na readout est. (NCT07324499)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Effect of Dexamethasone on Pl
 asma Levels of Bupivacaine and Dexamethasone After a Single-injection Inte
 rscalene Nerve Block.\nEstimated primary completion: 1 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07324499
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716176-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261206
DTEND;VALUE=DATE:20261207
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07716176)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Auricular Point Stimulation Pl
 us Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomitin
 g Caused by Docetaxel Plus Cyclophosphamide\nEstimated primary completion:
  6 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dex
 amethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07716176
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716189-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261206
DTEND;VALUE=DATE:20261207
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07716189)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Auricular Point Stimulation Pl
 us Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomitin
 g Caused by Trastuzumab Deruxtecan\nEstimated primary completion: 6 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethason
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 716189
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716228-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261206
DTEND;VALUE=DATE:20261207
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07716228)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Auricular Point Stimulation Pl
 us Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomitin
 g Caused by Gemcitabine Combined With Paclitaxel Protein-bound\nEstimated 
 primary completion: 6 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07716228
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06269900-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06269900)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Dexamethasone for Treating Sev
 ere Hospital-acquired Pneumonia in Critically Ill Patients With a Proinfla
 mmatory Phenotype\nEstimated primary completion: 15 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06269900
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819682-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07819682)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Dexamethasone and Duration of 
 Spinal Anesthesia\nEstimated primary completion: 15 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07819682
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672873-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Dexamethasone: Phase na readout est. (NCT07672873)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Local Dexamethasone Administr
 ation in Symptomatic Irreversible Pulpitis\nEstimated primary completion: 
 15 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dex
 amethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07672873
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07853664-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT07853664)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: Topical Dexamethasone/Diclof
 enac Hydrogel for Postoperative Pain and Swelling in Facial Soft Tissue In
 juries\nEstimated primary completion: 20 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07853664
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03729804-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03729804)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Carfilzomib\, Lenalidomide\, a
 nd Dexamethasone Versus Bortezomib\, Lenalidomide and Dexamethasone (KRd v
 s. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)\nEstimat
 ed primary completion: 28 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03729804
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03114865-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT03114865)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study of Blinatumomab in P
 atients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Mai
 ntenance\nEstimated primary completion: 30 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03114865
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05435547-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT05435547)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Preoperative Corticosteroids i
 n Autoimmune Thyroid Disease\nEstimated primary completion: 30 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0543554
 7
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07327931-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Dexamethasone: Phase na readout est. (NCT07327931)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: PENG Block Variants With Dexa
 methasone and Dexmedetomidine in Older Adults\nEstimated primary completio
 n: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07327931
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981209-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT05981209)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Elotuzumab\, CC-92480\, and De
 xamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38
 - and BCMA-Targeted Therapies\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059812
 09
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04161248-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT04161248)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Phase I Master Protocol of Nov
 el Combination Therapy for Patients With Relapsed or Refractory Aggressive
  B-Cell Lymphoma\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04161248
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05495035-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT05495035)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Study for Safety and Efficacy 
 of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refract
 ory Ph + ALL\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05495035
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388069-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07388069)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Study of TN-001 Topical Eyed
 rops for Keratoconus\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07388069
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099222-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07099222)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Efficacy of Non-weight Based
 \, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07099222
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05514990-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT05514990)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Bortezomib and Pembrolizumab
  With or Without Pelareorep for the Treatment of Relapsed or Refractory Mu
 ltiple Myeloma\, AMBUSH Trial\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055149
 90
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06489808-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06489808)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Linperlisib Combined With Immu
 nochemotherapy in Relapsed/Refractory LBCL\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dex
 amethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06489808
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727163-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05727163)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: FOLFOX Via HAI Plus Intravenou
 s Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or
  Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients\n
 Estimated primary completion: 31 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05727163
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05180097-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05180097)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Pembrolizumab and Brentuximab 
 Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Ly
 mphoma\nEstimated primary completion: 31 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05180097
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04216524-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04216524)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Venetoclax\, SL-401\, and Chem
 otherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
 \nEstimated primary completion: 31 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04216524
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04883242-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04883242)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Isatuximab\, Carfilzomib\, Pom
 alidomide\, and Dexamethasone for the Treatment of Relapsed or Refractory 
 Multiple Myeloma\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04883242
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02436707-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT02436707)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Novel Combination Therapy in t
 he Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02436707
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862468-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04862468)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Perivenous Dexamethasone Thera
 py: Examining Reduction of Inflammation After Thrombus Removal to Yield Be
 nefit in Acute Femoropopliteal DVT\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethaso
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4862468
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04638790-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04638790)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: First Line Chemotherapy for Cl
 assical Hodgkin Lymphoma in Russia (HL-Russia-1)\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04638790
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01863550-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT01863550)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Bortezomib or Carfilzomib With
  Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed 
 Multiple Myeloma\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT01863550
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692010-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT06692010)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Comparison Between Clavipector
 al Fascia Block & Interscalene Brachial Plexus Block as Regard Adequacy of
  Anesthesia in Clavicle Surgeries\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethason
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 692010
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06924424-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase na readout est. (NCT06924424)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Aponermin\, Pomalidomide\, De
 xamethasone for Patients With Relapsed/ Refractory Multiple Myeloma\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06924424
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06410443-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase na readout est. (NCT06410443)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Efficacy and Safety of Local 
 Glucocorticoids for the Treatment of Acute Radiation-Induced Intestinal In
 jury\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06410443
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04270175-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04270175)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Daratumumab\, Pomalidomide\, a
 nd Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Pati
 ents Previously Exposed to Daratumumab\nEstimated primary completion: Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethaso
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4270175
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655908-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Dexamethasone: Phase na readout est. (NCT07655908)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Catheter Redosing of Autonomi
 c Neural Blockade After Sleeve Gastrectomy\nEstimated primary completion: 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamet
 hasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07655908
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268704-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT06268704)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Particulate vs. Non-Particulat
 e Steroid for Sacroiliac Joint Injection\nEstimated primary completion: 1 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamet
 hasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06268704
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06715709-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT06715709)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: How Many Dexamethasone Doses S
 hould Be Given Perioperatively?\nEstimated primary completion: 1 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067157
 09
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07289620-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Dexamethasone: Phase na readout est. (NCT07289620)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Dexamethasone vs Dexmedetomid
 ine vs Combination as Adjuvants to Popliteal Sciatic Nerve Block in Childr
 en\nEstimated primary completion: 1 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07289620
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474909-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Dexamethasone: Phase na readout est. (NCT07474909)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Perineural vs Intravenous Dex
 amethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surge
 ry\nEstimated primary completion: 1 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07474909
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03829371-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270103
DTEND;VALUE=DATE:20270104
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT03829371)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: STUDY COMPARING TWO STANDARD T
 REATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AF
 FECTED BY MULTIPLE MYELOMA\nEstimated primary completion: 3 January 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03829371
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519085-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT05519085)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Evaluate Mezigdomid
 e\, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide\, Bortezomib
  and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multi
 ple Myeloma (RRMM)\nEstimated primary completion: 10 January 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05519085
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008795-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06008795)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: BLOCK-SAH - PPF-Block for Post
 -SAH Headache\nEstimated primary completion: 15 January 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06008795
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722091-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Dexamethasone: Phase na readout est. (NCT07722091)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Intraperitoneal Dexamethasone
  Spraying on Vagal Nerve-Rich Areas for Prevention of Hoarseness After Upp
 er Abdominal Surgery\nEstimated primary completion: 30 January 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07722091
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07617246-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07617246)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: The Efficacy and Safety of Fos
 rolapitant and Palonosetron Hydrochloride for Injection in Preventing Naus
 ea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Pa
 tients With Esophageal Cancer and Lung Cancer\nEstimated primary completio
 n: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 examethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07617246
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07378215-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07378215)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: The Effect of Corticosteroids 
 on Quality of Life Following Total Hip Arthroplasty: HIPSTER Study\nEstima
 ted primary completion: February 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07378215
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04268498-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04268498)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of Daratumumab\, Carfi
 lzomib\, Lenalidomide\, and Dexamethasone in Patients With Newly-Diagnosed
  Multiple Myeloma\nEstimated primary completion: 1 February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04268498
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605065-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07605065)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Dexamethasone Plus Metoclopram
 ide Versus Paracetamol/NSAIDs for Primary Headache\nEstimated primary comp
 letion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07605065
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05736419-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05736419)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of Immune Suppression 
 Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Go
 ing to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)\nEst
 imated primary completion: 9 February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05736419
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04508790-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04508790)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Leflunomide\, Pomalidomide\, a
 nd Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myel
 oma\nEstimated primary completion: 14 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04508790
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334379-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07334379)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Interleukin-6 Guided Treatment
  With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Res
 piratory Symptoms - a Feasibility Study\nEstimated primary completion: 20 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexame
 thasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07334379
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04133636-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04133636)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of JNJ-68284528\, a Ch
 imeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Mat
 uration Antigen (BCMA) in Participants With Multiple Myeloma\nEstimated pr
 imary completion: 26 February 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04133636
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064993-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07064993)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Effects of Intraarticular Tram
 adol and Tramadol-Dexamethasone on Postoperative Pain After Knee Arthrosco
 py\nEstimated primary completion: 26 February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07064993
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04329325-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04329325)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Blinatumomab and Tyrosine Kina
 se Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute
  Lymphoblastic Leukemia\nEstimated primary completion: March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04329325
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04166565-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04166565)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Daratumumab Combined With Bort
 ezomib\, Cyclophosphamide and Dexamethasone for the Treatment of Multiple 
 Myeloma Patients Presenting With Extramedullary Disease\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04166565
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05787574-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05787574)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of Treatment of Inflam
 mation Before Stem Cell Transplant in People With a Primary Immune Regulat
 ory Disorder (PIRD) and/or an Autoinflammatory Condition\nEstimated primar
 y completion: March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05787574
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04150614-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT04150614)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: BMT-08: A Comparative Effectiv
 eness Study of Transdermal Granisetron to Ondansetron\nEstimated primary c
 ompletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04150614
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073209-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dexamethasone: Phase na readout est. (NCT07073209)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: PENG vs Femoral Block for Hip
  Fracture Analgesia\nEstimated primary completion: March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07073209
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504822-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270318
DTEND;VALUE=DATE:20270319
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07504822)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Comparative Effectiveness of
  Clindamycin-Retinoid\, Clindamycin-Retinoid-Dexamethasone\, and 10% SM-hU
 CMSC Secretome Gel in the Improvement of Mild-to-Moderate Acne Vulgaris\nE
 stimated primary completion: 18 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07504822
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03710772-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT03710772)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Ibrutinib\, Rituximab\, Veneto
 clax\, and Combination Chemotherapy in Treating Patients With Newly Diagno
 sed Mantle Cell Lymphoma\nEstimated primary completion: 22 March 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03710772
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Study to Evaluate CCS1477 (I
 nobrodib) in Haematological Malignancies\nEstimated primary completion: 31
  March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexameth
 asone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04068597
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508983-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06508983)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Clinical Study Comparing SG3
 01 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and De
 xamethasone in Relapsed or Refractory Multiple Myeloma Patients\nEstimated
  primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06508983
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07584200-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dexamethasone: Phase na readout est. (NCT07584200)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Comparison of Spinal Anesthes
 ia With Intrathecal Morphine Versus PENG Block With or Without Dexamethaso
 ne in Hip Arthroplasty\nEstimated primary completion: 31 March 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07584200
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Selinexor and Backbone Treat
 ments of Multiple Myeloma Patients\nEstimated primary completion: April 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0234304
 2
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT05558319)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: NDMM Patients Candidates for A
 SCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide\nEstimate
 d primary completion: April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04266977-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dexamethasone: Phase na readout est. (NCT04266977)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Restrictive Use of Dexamethas
 one in Glioblastoma\nEstimated primary completion: April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04266977
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07568184-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dexamethasone: Phase na readout est. (NCT07568184)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: A Randomized Trial of Intraty
 mpanic Drug Delivery: Evaluating the Efficacy and Safety of Dexamethasone-
 Loaded Exosomes Versus Standard Therapy in Acute Sensorineural Hearing Los
 s.\nEstimated primary completion: April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07568184
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06383572-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06383572)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Phase I/II Study of Engineer
 ed T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With L
 ymphodepleting Chemotherapy for the Management of Relapse/Refractory Myelo
 id Malignancies\nEstimated primary completion: 1 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06383572
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04835129-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04835129)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Isatuximab\, Pomalidomide\, El
 otuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma\
 nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04835129
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303792-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05303792)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Comparing Inotuzumab Combined 
 With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Pl
 us Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leuk
 emia\nEstimated primary completion: 1 April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05303792
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356571-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06356571)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study to Investigate Subcuta
 neous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone 
 in Adult Participants With Relapsed and/or Refractory Multiple Myeloma\nEs
 timated primary completion: 1 April 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06356571
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Investigate the Cli
 nical Benefit of Isatuximab in Combination With Bortezomib\, Lenalidomide 
 and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Elig
 ible for Transplant\nEstimated primary completion: 5 April 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03319667
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559331-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270408
DTEND;VALUE=DATE:20270409
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07559331)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: High-Dose Dexamethasone Combin
 ed With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo
  in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia\nE
 stimated primary completion: 8 April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07559331
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06622005-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT06622005)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: SX-682 in Combination With Car
 filzomib\, Daratumumab-Hyaluronidase\, and Dexamethasone in Patients With 
 Relapsed or Refractory Multiple Myeloma\nEstimated primary completion: 10 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexametha
 sone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06622005
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187167-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270412
DTEND;VALUE=DATE:20270413
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07187167)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Efficacy and Safety of the RD 
 Regimen(Lenalidomide\, Dexamethasone) for Rosai-Dorfman Disease\nEstimated
  primary completion: 12 April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07187167
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548736-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270424
DTEND;VALUE=DATE:20270425
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07548736)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Improvement Effect of Dexameth
 asone Enema for Acute Radiation-induced Rectal Injury\nEstimated primary c
 ompletion: 24 April 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07548736
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04432012-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT04432012)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: A Study to Compare Different W
 ays of Steroid Administration After Total Knee Implantation\nEstimated pri
 mary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04432012
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00492999-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT00492999)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Hepatic Arterial Infusion With
  Floxuridine and Dexamethasone Combined With Combination Chemotherapy in T
 reating Patients With Colorectal Cancer That Has Spread to the Liver\nEsti
 mated primary completion: May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT00492999
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04176718-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04176718)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Daratumumab\, Carfilzomib\, Po
 malidomide\, Dexamethasone In MM\nEstimated primary completion: May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04176718
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04891289-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04891289)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Gemcitabine and Oxaliplatin Ch
 emotherapy With or Without a Floxuridine and Dexamethasone Pump in People 
 With Cholangiocarcinoma That Cannot Be Removed With Surgery\nEstimated pri
 mary completion: May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04891289
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06259006-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06259006)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: TREAT-SC: Early\, Short Course
  Oral Dexamethasone for the Treatment of Sydenham Chorea in Children\nEsti
 mated primary completion: May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06259006
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494136-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07494136)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Dose Dependent Steroid Injecti
 ons\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07494136
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911202-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07911202)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Dexmedetomidine Versus Dexamet
 hasone as Adjuvants to Bupivacaine in Ultrasound-Guided Sphenopalatine Gan
 glion Block for Functional Endoscopic Sinus Surgery\nEstimated primary com
 pletion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/de
 xamethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07911202
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432399-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07432399)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Effect of Perioperative Lidoca
 ine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery 
 (PILDI Study)\nEstimated primary completion: 1 May 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07432399
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627751-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06627751)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Mezigdomide\, Carfilzomib\, an
 d Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myelo
 ma in Patients With Extramedullary Disease\nEstimated primary completion: 
 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexametha
 sone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06627751
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06988124-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Dexamethasone: Phase na readout est. (NCT06988124)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Dexamethasone Palmitate for P
 ONV After Craniotomy\nEstimated primary completion: 1 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06988124
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04754945-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270506
DTEND;VALUE=DATE:20270507
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT04754945)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Isatuximab as Upfront Therapy 
 for the Treatment of High Risk AL Amyloidosis\nEstimated primary completio
 n: 6 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexame
 thasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04754945
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06988488-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06988488)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study to Determine the Rec
 ommended Dose and Schedule\, and Evaluate the Safety and Preliminary Effic
 acy of Mezigdomide in Combination With Elranatamab in Participants With Re
 lapsed and/or Refractory Multiple Myeloma\nEstimated primary completion: 3
 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexametha
 sone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06988488
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974604-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06974604)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Preventing Dato-DXd Associated
  Stomatitis With Dexamethasone Mouthwash\, TROPION-DM\nEstimated primary c
 ompletion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06974604
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02494882-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT02494882)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Adding Ruxolitinib to a Combin
 ation of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Ne
 wly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemi
 a Patients Aged 40 Years or Older\nEstimated primary completion: June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT02494882
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812259-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07812259)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Clinical Tolerance of an Intra
 parotid Injection of Bupivacaine\, Combined With Dexamethasone\, After Par
 otidectomy for Benign Tumor\nEstimated primary completion: June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07812259
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01297764-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT01297764)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study of Carfilzomib\, Len
 alidomide\, Vorinostat\, and Dexamethasone in Relapsed and/or Refractory M
 ultiple Myeloma\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT01297764
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02899052-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT02899052)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Study of Venetoclax in Combina
 tion With Carfilzomib and Dexamethasone in Participants With Relapsed or R
 efractory Multiple Myeloma (MM)\nEstimated primary completion: June 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02899052
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294118-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07294118)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Infusion of Lidocaine and Ster
 oids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage\nEstim
 ated primary completion: June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07294118
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06212336-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT06212336)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: ISTH/ANRS 0409s INTEGRATE La
 ssa Fever Study\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06212336
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03206671-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03206671)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Treatment Protocol of the NHL-
 BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and L
 eukemia in Children and Adolescents\nEstimated primary completion: June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0320667
 1
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06590402-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT06590402)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Anterior Femoral and Adductor 
 Canal Nerve Blocks in Peds Knees\nEstimated primary completion: June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06590402
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07760272-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase na readout est. (NCT07760272)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Effect Of Intracuff Dexametha
 sone On Postoperative Sore Throat In Patients Undergoing Laparoscopic Chol
 ecystectomy\nEstimated primary completion: June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07760272
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03715478-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT03715478)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Multi-Center Study of GSK285
 7916 in Combination With Pomalidomide and Dex\nEstimated primary completio
 n: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexam
 ethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03715478
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550803-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Dexamethasone: Phase na readout est. (NCT07550803)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Effect of Intraoperative Dexa
 methasone on Early Postoperative Sleep Quality in Patients Undergoing Nasa
 l Surgery\nEstimated primary completion: 1 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07550803
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319730-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT05319730)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study to Evaluate Investig
 ational Agents With or Without Pembrolizumab (MK-3475) in Participants Wit
 h Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1
  Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475
 -06B)\nEstimated primary completion: 11 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05319730
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699744-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07699744)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Intravenous Dexamethasone With
  Single-Shot Versus Continuous Brachial Plexus Block for Rebound Pain Afte
 r Shoulder Surgery\nEstimated primary completion: 15 June 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07699744
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909826-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05909826)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Carfilzomib\, Oral Cyclophosph
 amide\, and Dexamethasone for RRMM\nEstimated primary completion: 30 June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05909
 826
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02427620-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT02427620)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Ibrutinib\, Rituximab\, and Co
 nsolidation Chemotherapy in Treating Young Patients With Newly Diagnosed M
 antle Cell Lymphoma\nEstimated primary completion: 30 June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT02427620
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06811675-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT06811675)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: The Efficacy of Dexamethasone 
 in Combination With N-acetylcysteine in Preventing Neurocognitive Sequelae
  Due to Carbon Monoxide Poisoning\nEstimated primary completion: 30 June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068116
 75
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341854-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase na readout est. (NCT07341854)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Dexamethasone Palmitate for P
 ostoperative Pain\nEstimated primary completion: 30 June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07341854
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581470-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase na readout est. (NCT07581470)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Intravenous Dexamethasone (0 
 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in T
 otal Hip Arthroplasty\nEstimated primary completion: 30 June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07581470
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06574048-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06574048)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Carbon Monoxide Hyperbaric O
 xygen With Steroid Therapy\nEstimated primary completion: July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06574048
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07479979-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07479979)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Study of Selinexor With Carf
 ilzomib\, Isatuximab and Dexamethasone for Patients With Relapsed and/or R
 efractory Multiple Myeloma\nEstimated primary completion: July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07479979
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556332-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT03556332)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of Carfilzomib\, Lenal
 idomide\, Dexamethasone and Daratumumab for Patients With Relapsed/Refract
 ory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation\nEs
 timated primary completion: July 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03556332
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287826-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07287826)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Using a Steroid Mouthwash to P
 revent Mouth Sores During Chemotherapy\nEstimated primary completion: July
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0728
 7826
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07032714-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07032714)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Mezigdomide and Talquetamab in
  Relapsed and Refractory Multiple Myeloma\nEstimated primary completion: 1
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexametha
 sone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07032714
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04947189-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT04947189)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Seviteronel in Combination W
 ith Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative 
 Breast Cancer\nEstimated primary completion: 1 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04947189
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04124497-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04124497)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Trial for Relapsed and Relap
 sed/Refractory Multiple Myeloma Patients\nEstimated primary completion: 1 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethas
 one#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04124497
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04915248-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04915248)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Study to Evaluate Combined Tre
 atment of Daratumumab\, Bortezomib and Dexamethasone in PBL Patients.\nEst
 imated primary completion: 1 July 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04915248
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07607691-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Dexamethasone: Phase na readout est. (NCT07607691)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Ultrasound-Guided PENG Block 
 for Chronic Shoulder Pain\nEstimated primary completion: 1 July 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07607691
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132685-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06132685)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Post-Operative Dosing of Dexam
 ethasone in Patients With Brain Tumors After a Craniotomy\, PODS Trial\nEs
 timated primary completion: 30 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06132685
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348108-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT06348108)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Talquetamab in Combination Wit
 h Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
 \nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06348108
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07615595-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07615595)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Dexamethasone to Prevent Side 
 Effects of Spinal Anesthesia in Cesarean Delivery\nEstimated primary compl
 etion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07615595
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03909412-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT03909412)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Carfilzomib Based Chemotherapy
  Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma\nEs
 timated primary completion: August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03909412
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662200-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07662200)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: A Simplified Regimen to Preven
 t Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Pa
 tients Receiving Chemotherapy\nEstimated primary completion: August 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07662200
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05972135-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05972135)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Outpatient Administration of T
 eclistamab or Talquetamab for Multiple Myeloma\nEstimated primary completi
 on: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexa
 methasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05972135
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01920737-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT01920737)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Novel "Pediatric-Inspired" R
 egimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Ne
 wly Diagnosed Ph Negative Acute Lymphoblastic Leukemia\nEstimated primary 
 completion: August 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT01920737
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03618537-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT03618537)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Ixazomib Maintenance Study in 
 Patients With AL Amyloidosis\nEstimated primary completion: August 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03618537
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05665140-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT05665140)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: Expression-linked and R-ISS-
 adapted Stratification for First Line Therapy in Multiple Myeloma Patients
 \nEstimated primary completion: August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05665140
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00572169-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT00572169)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: UARK 2006-66\, Total Therapy 3
 B: An Extension of UARK 2003-33 Total Therapy\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexam
 ethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT00572169
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134075-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07134075)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Intracochlear Injection of Glu
 cocorticoid\nEstimated primary completion: 1 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07134075
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204041-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07204041)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Efficacy and Safety of XTD Reg
 imen (Selinexor\, Thalidomide and Dexamethasone) in Adult Patients With Re
 lapsed/Refractory LCH\nEstimated primary completion: 1 August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07204041
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03136146-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT03136146)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Combination Chemotherapy in Tr
 eating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia\,
  Lymphoblastic Lymphoma\, Burkitt Lymphoma/Leukemia\, or Double-Hit Lympho
 ma/Leukemia\nEstimated primary completion: 1 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03136146
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550141-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06550141)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Emapalumab Prevention of CAR-T
  Cell Associated Toxicities\nEstimated primary completion: 1 August 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06550141
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855341-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07855341)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Low-Volume Pericapsular Nerve 
 Group (PENG) Block With Dexamethasone vs Standard-Volume PENG Block After 
 Total Hip Arthroplasty\nEstimated primary completion: 31 August 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07855341
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451771-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT05451771)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Venetoclax-Dexamethasone in 
 Relapsed and/or Refractory t(11\;14) Amyloidosis\nEstimated primary comple
 tion: September 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05451771
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05279092-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05279092)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Yale Steroid Enhanced Versus E
 xparel Nerveblock TKA RCT Study\nEstimated primary completion: September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT052790
 92
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05736549-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05736549)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Yale Steroid Enhanced Versus E
 xparel Nerveblock TKA Part 2\nEstimated primary completion: September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05736549
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05895838-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT05895838)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: The Danish Out-of-Hospital Car
 diac Arrest Study\nEstimated primary completion: September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05895838
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444710-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07444710)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Testing the Addition of an Ant
 i-Cancer Drug\, Glofitamab\, to the Usual Chemotherapy Treatment (Alternat
 ing R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma\nEstimate
 d primary completion: 1 September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07444710
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04776395-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04776395)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Iberdomide Alone or in Combina
 tion With Dexamethasone for the Treatment of Intermediate- or High-Risk Sm
 oldering Multiple Myeloma\nEstimated primary completion: 1 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04776395
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04790474-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04790474)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Ixazomib-pomalidomide-dexameth
 asone as Second or Third-line Combination Treatment for Patients With Rela
 psed and Refractory Multiple Myeloma Previously Treated With Daratumumab\,
  Lenalidomide and Bortezomib\nEstimated primary completion: 1 September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0479047
 4
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04096066-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04096066)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Trial That Compare Two Treat
 ments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant\nEst
 imated primary completion: 1 September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04096066
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677215-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Dexamethasone: Phase na readout est. (NCT07677215)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: ACB and iPACK Blocks With Int
 ravenous Dexamethasone and Perineural Dexmedetomidine in Total Knee Arthro
 plasty\nEstimated primary completion: 1 September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07677215
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05323149-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270910
DTEND;VALUE=DATE:20270911
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT05323149)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Dexamethasone in Traumatic Bra
 in Injury\nEstimated primary completion: 10 September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05323149
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04643002-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Isatuximab in Combination Wi
 th Novel Agents in RRMM - Master Protocol\nEstimated primary completion: 1
 3 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dex
 amethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04643002
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438119-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07438119)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Efficacy Comparison of DExamet
 hasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept M
 onotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patient
 s\nEstimated primary completion: 15 September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07438119
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03914625-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03914625)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Investigate Blinatu
 momab in Combination With Chemotherapy in Patients With Newly Diagnosed B-
 Lymphoblastic Leukemia\nEstimated primary completion: 30 September 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03914625
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07345819-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dexamethasone: Phase na readout est. (NCT07345819)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Dexamethasone vs. Placebo in 
 Children and Youth Hospitalized for Orbital Cellulitis\nEstimated primary 
 completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07345819
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00869232-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT00869232)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: UARK 2008-02 A Trial for High-
 risk Myeloma Evaluating Accelerating and Sustaining Complete Remission\nEs
 timated primary completion: October 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT00869232
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03004287-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT03004287)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: 2015-12: A Study Exploring the
  Use of Early and Late Consolidation/Maintenance Therapy\nEstimated primar
 y completion: October 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03004287
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827157-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT07827157)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: Comparison of Dexmedetomidin
 e Versus Dexamethasone as Adjuvants to Bupivacaine in Ultrasound-Guided Er
 ector Spinae Plane Block for Acute Pain Management in Patients With Trauma
 tic Rib Fractures\nEstimated primary completion: October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07827157
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847047-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07847047)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Safety and Efficacy of Dexamet
 hasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries 
 for Postoperative Pain Management\nEstimated primary completion: October 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078470
 47
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878599-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT06878599)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Intratympanic Injection of Dex
 amethasone With Hyaluronic Acid in Treatment of Sudden Sensorineural Heari
 ng Loss\nEstimated primary completion: October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06878599
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07360431-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07360431)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Granisetron Combined With Dexa
 methasone or Metoclopramide for PONV Prevention After Laparoscopic Cholecy
 stectomy\nEstimated primary completion: October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07360431
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05721027-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT05721027)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Ibuprofen With or Without Dexa
 methasone for Acute Radicular Low Back Pain.\nEstimated primary completion
 : October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexam
 ethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05721027
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06603662-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT06603662)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Systemic Oral Glucocorticoids 
 for the Treatment of Acute Osteoarthritis Pain in the Emergency Department
 \nEstimated primary completion: October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06603662
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793760-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07793760)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Dexamethasone Versus Ondansetr
 on for Preventing Post-Spinal Hypotension in Preeclampsia\nEstimated prima
 ry completion: October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07793760
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044557-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase na readout est. (NCT07044557)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: MeDex: No Perioperative Dexam
 ethasone in Brain Metastases\nEstimated primary completion: October 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07044557
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699276-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07699276)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Steroid Sparing Regimen With O
 lanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin\n
 Estimated primary completion: 1 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07699276
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05208307-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271021
DTEND;VALUE=DATE:20271022
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05208307)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Belantamab Mafodotin\, Pomalid
 omide and Dexamethasone for the Treatment of High-Risk Myeloma\nEstimated 
 primary completion: 21 October 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05208307
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861573-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT02861573)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Study of Pembrolizumab (MK-3
 475) Combination Therapies in Metastatic Castration-Resistant Prostate Can
 cer (MK-3475-365/KEYNOTE-365)\nEstimated primary completion: 22 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0286157
 3
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03763162-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT03763162)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Daratumumab\, Bortezomib\, and
  Dexamethasone Followed by Daratumumab\, Ixazomib\, and Dexamethasone in T
 reating Patients With Relapsed or Refractory Multiple Myeloma\nEstimated p
 rimary completion: 30 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03763162
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01424982-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT01424982)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Combination Chemotherapy and P
 onatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leuke
 mia\nEstimated primary completion: 31 October 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT01424982
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06901817-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06901817)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of the Safety and Effi
 cacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection 
 for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer wi
 th Leptomeningeal Metastases\nEstimated primary completion: November 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06901817
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07018050)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Phase II Study of QLS32015 Com
 bination Therapy in the Treatment of Multiple Myeloma\nEstimated primary c
 ompletion: November 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02659293-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT02659293)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Trial of Carfilzomib\, Lenalid
 omide\, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant
  for Multiple Myeloma\nEstimated primary completion: November 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT02659293
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07837674-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Dexamethasone: Phase na readout est. (NCT07837674)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Impact of Intravenous Dexamet
 hasone on the Duration of Motor and Sensory Block Following Spinal Anesthe
 sia With Chloroprocaine\nEstimated primary completion: November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07837674
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918079-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07918079)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Netupitant/Palonosetron for Pr
 evention of Nausea and Vomiting in Breast Cancer ADC Therapy\nEstimated pr
 imary completion: 1 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07918079
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03150693-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03150693)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Inotuzumab Ozogamicin and Fron
 tline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute L
 ymphoblastic Leukemia\nEstimated primary completion: 1 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03150693
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05023369-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT05023369)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: This is a Study to Verify if P
 eriarticular Hip Injection of Corticosteroid After Hip Replacement Reduce 
 the Pain and the Hospitalisation Time\nEstimated primary completion: 1 Nov
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexametha
 sone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05023369
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979596-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06979596)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of MK-5684 in People W
 ith Certain Solid Tumors (MK-5684-015/OMAHA-015)\nEstimated primary comple
 tion: 4 November 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06979596
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975997-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04975997)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Open-label Study Comparing Ibe
 rdomide\, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab\, Bort
 ezomib\, and Dexamethasone (DVd) in Participants With Relapsed or Refracto
 ry Multiple Myeloma (RRMM)\nEstimated primary completion: 16 November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04975997
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07210047-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07210047)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Study of HuL001 in Relapsed/
 Refractory Multiple Myeloma Patients\nEstimated primary completion: 30 Nov
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexametha
 sone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07210047
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409702-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT06409702)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Treatment of High-risk Newly D
 iagnosed Multiple Myeloma With Minimal Residual Disease Detection\nEstimat
 ed primary completion: 30 November 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06409702
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224334-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07224334)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Role of Alpha-to-beta Cell Com
 munication to Adapt Insulin Secretion to Insulin Resistance.\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07224334
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433947-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT06433947)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Study to Assess Safety and Tol
 erability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple
  Myeloma\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06433947
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04392037-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04392037)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Iberdomide Combined With Low-d
 ose Cyclophosphamide and Dexamethasone\nEstimated primary completion: Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethas
 one#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04392037
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04891809-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04891809)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Isatuximab in Combination With
  Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04891809
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00871013-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT00871013)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Trial for Patients Not Qualify
 ing for TT4 and TT5 Protocols Because of Prior Therapy\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT00871013
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06390319-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06390319)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Adding Dasatinib Or Venetoclax
  To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lympho
 blastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukem
 ia (MPAL)\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06390319
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742138-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06742138)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: To Evaluate the Efficacy and S
 afety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma\nEstimated prima
 ry completion: December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06742138
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07297329)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Evaluate the Safety
  and Efficacy of SCTC21C in Combination With Bortezomib\, Lenalidomide and
  Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligi
 ble for Transplant\nEstimated primary completion: December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07297329
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388602-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07388602)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Evaluate the Safety
  and Efficacy of SCTC21C in Combination With Bortezomib\, Cyclophosphamide
 \, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain
  Amyloidosis (NDSLCA)\nEstimated primary completion: December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07388602
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Study Assessing Activity of In
 travenous (IV) Etentamig Monotherapy Versus Standard Available Therapies i
 n Adult Participants With Relapsed or Refractory Multiple Myeloma\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05635227-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase na readout est. (NCT05635227)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Dexamethasone\, Olanzapine\, 
 Hemodynamics\, and Ventilation in Cardiac Surgery\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05635227
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980727-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06980727)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Comparative Efficacy of IV Dex
 amethasone vs. Nebulized Terbutaline for Renal Colic Pain in the ED\nEstim
 ated primary completion: 1 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06980727
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05793060-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT05793060)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Dexmedetomidine Versus Dexamet
 hasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block\
 nEstimated primary completion: 1 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05793060
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614802-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07614802)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Exparel and Dexamethasone\nEst
 imated primary completion: 1 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07614802
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890220-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07890220)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Intravenous Dexamethasone for 
 ESP Block Analgesia in Children Undergoing Idiopathic Scoliosis Surgery\nE
 stimated primary completion: 1 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07890220
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05660473-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05660473)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Pediatric-inspired Regimen Com
 bined With Venetoclax for Adolescent and Adult Patients With de Novo Phila
 delphia Chromosome-Negative Acute Lymphoblastic Leukemia\nEstimated primar
 y completion: 15 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05660473
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04775550-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04775550)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: DARA RVD For High Risk SMM\nEs
 timated primary completion: 20 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04775550
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01371630-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271225
DTEND;VALUE=DATE:20271226
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT01371630)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Inotuzumab Ozogamicin and Co
 mbination Chemotherapy in Treating Patients With Acute Lymphoblastic Leuke
 mia\nEstimated primary completion: 25 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT01371630
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06016465-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT06016465)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Does Nerve Block + Oral Dexame
 thasone Reduce Recurrence of Headache Within 72 Hrs?\nEstimated primary co
 mpletion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06016465
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Compare the Efficac
 y and Safety of BMS-986393 Versus Standard Regimens in Adult Participants 
 With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUI
 NTESSENTIAL-2)\nEstimated primary completion: 30 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06615479
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03132454-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT03132454)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Palbociclib and Sorafenib\, De
 citabine\, or Dexamethasone in Treating Patients With Recurrent or Refract
 ory Leukemia\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03132454
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03719105-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT03719105)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Chemoimmunotherapy and Allogen
 eic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03719105
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04225611-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT04225611)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Therapeutic Contact Lens Dru
 g Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Ede
 ma\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04225611
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03376672-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT03376672)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Ixazomib Plus Lenalidomide Plu
 s Dexamethasone for Newly Diagnosed Myeloma Patients\nEstimated primary co
 mpletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03376672
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03583255-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT03583255)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Physical Activity With or With
 out Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Loca
 lly Advanced\, Metastatic\, or Recurrent Cancer\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03583255
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335887-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07335887)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Sonrotoclax Plus Dexamethasone
  With or Without Daratumumab Regimen in Patients With t(11\;14) Primary AL
  Amyloidosis\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07335887
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811986-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07811986)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: HP-001 Plus Dexamethasone for 
 Relapsed/Refractory Multiple Myeloma With Extramedullary Disease\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07811986
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645718-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05645718)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Study of Pedi-cRIB: Mini-Hyper
 -CVD With Condensed Rituximab\, Inotuzumab Ozogamicin and Blinatumomab (cR
 IB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocyt
 ic Leukemia\nEstimated primary completion: 31 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05645718
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05286814-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05286814)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: PDS01ADC in Combination With H
 epatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With 
 Metastatic Colorectal Cancer\, Intrahepatic Cholangiocarcinoma\, or Metast
 atic Adrenocortical Carcinoma\nEstimated primary completion: 31 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT052868
 14
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616584-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT06616584)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: Adding the Immunotherapy Dru
 g Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lu
 ng Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immuno
 therapy (An Expanded Lung-MAP Treatment Trial)\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06616584
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566328-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04566328)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Testing the Use of Combination
  Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma\, the EQU
 ATE Trial\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04566328
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05024344-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase na readout est. (NCT05024344)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: ESP Block vs Control for Pain
  Control Following Percutaneous Nephrolithotomy\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05024344
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652879-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07652879)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: KCD (Carfilzomib/Cyclophospham
 ide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Synd
 rome\nEstimated primary completion: January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07652879
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04414475-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04414475)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of Selinexor (Seli) + 
 Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM)\, S
 eli and Bortezomib + LDD in Triple-class Refractory MM.\nEstimated primary
  completion: January 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04414475
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299435-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Dexamethasone: Phase na readout est. (NCT07299435)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Effect of the Combination of 
 Dexamethasone and BIS Monitoring on Reducing Postoperative Nausea and Vomi
 ting in Children\nEstimated primary completion: January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07299435
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863259-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT06863259)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Study of Inotuzumab Ozogamicin
 \, Venetoclax\, and Dexamethasone for Relapsed B-cell ALL\nEstimated prima
 ry completion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06863259
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207305-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280102
DTEND;VALUE=DATE:20280103
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06207305)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Phase I/II Study of Intrap
 eritoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinom
 a\nEstimated primary completion: 2 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06207305
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357597-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280104
DTEND;VALUE=DATE:20280105
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07357597)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: An Open-label\, Single-arm Stu
 dy of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatiti
 s in Eligible Patients With Metastatic or Inoperable Locally Recurrent Bre
 ast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Recep
 tor-Mutated Non-small Cell Lung Cancer.\nEstimated primary completion: 4 J
 anuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexameth
 asone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07357597
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106945-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06106945)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: AZD0305 as Monotherapy or in
  Combination With Anticancer Agents in Participants With Multiple Myeloma\
 nEstimated primary completion: 24 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06106945
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992128-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06992128)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Romiplostim N01 Combined With 
 Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Prim
 ary Immune Thrombocytopenia: A Multicenter\, Interventional Trial\nEstimat
 ed primary completion: 31 January 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06992128
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841210-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07841210)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Fosrolapitant and Palonosetron
  for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors\nEs
 timated primary completion: 31 January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07841210
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052201-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07052201)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Dexamethasone Regimens for BPD
  Prevention in Preterm Infants\nEstimated primary completion: 31 January 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070522
 01
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04661137-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04661137)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of Selinexor\, in Comb
 ination With Carfilzomib\, Daratumumab or Pomalidomide in Patients With Mu
 ltiple Myeloma\nEstimated primary completion: February 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04661137
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07084285-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07084285)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Cervical Facet Injection of Co
 rticosteroids for the Management of Cervicobrachialgia\nEstimated primary 
 completion: February 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07084285
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072234-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07072234)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Phase I Study of Allogeneic Tr
 ansforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells i
 n Treatment Refractory Clear Cell Renal Cell Carcinoma\nEstimated primary 
 completion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07072234
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743957-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07743957)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Selinexor\, Daratumumab\, and 
 Dexamethasone (XDd) for Light-Chain Cardiac Amyloidosis\nEstimated primary
  completion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07743957
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07914309-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280208
DTEND;VALUE=DATE:20280209
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07914309)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Dexamethasone De-Escalation in
  Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer\nEstimat
 ed primary completion: 8 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07914309
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05272826-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05272826)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Study of Iberdomide\, Bortezom
 ib\, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients\
 nEstimated primary completion: March 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05272826
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879379-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT06879379)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: KPD Consolidation After ASCT
  in NDMM Patients\nEstimated primary completion: March 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06879379
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843849-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07843849)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Corticosteroid for Diabetic Ma
 cular Edema (DME) Study\nEstimated primary completion: March 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07843849
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04747912-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04747912)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Study of Chemotherapy-Free Ind
 uction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogam
 icin (InO)\nEstimated primary completion: 1 March 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04747912
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07763210-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07763210)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Intrathecal Cytarabine and Hyd
 rocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T 
 Therapy for Non Hodgkin Lymphoma\nEstimated primary completion: 1 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0776321
 0
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05530421-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280326
DTEND;VALUE=DATE:20280327
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05530421)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Selinexor\, Venetoclax\, and D
 examethasone (XVenD) in t(11\;14)-Positive Relapsed/Refractory Multiple My
 eloma\nEstimated primary completion: 26 March 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05530421
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341867-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07341867)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Systemic Anti-Cancer Therapy D
 ose Modifications for Individuals With Duffy Null Phenotype\nEstimated pri
 mary completion: 31 March 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07341867
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07556952-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07556952)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Dex & Mastectomy Pain\nEstimat
 ed primary completion: 31 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07556952
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07343817-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07343817)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: IV Injection of Metoclopramide
  With or Without Dexamethasone\nEstimated primary completion: 1 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07343817
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540728-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07540728)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Trans-round Window Membrane In
 tracochlear Steroid\nEstimated primary completion: 20 April 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07540728
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353022-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06353022)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Minimal Residual Disease-based
  Strategy With T-Cell Redirector After Treatment With Daratumumab\, Bortez
 omib\, Lenalidomide\, and Dexamethasone (D-VRd) in Newly Diagnosed Multipl
 e Myeloma\nEstimated primary completion: 26 April 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06353022
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07442890-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Dexamethasone: Phase na readout est. (NCT07442890)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: A Cohort Study on the Prevent
 ion of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lun
 g Cancer Using Rolapitant and Palonosetron\nEstimated primary completion: 
 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexame
 thasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07442890
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533748-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06533748)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Therapy for Newly Diagnosed Pa
 tients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma\nEs
 timated primary completion: May 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06533748
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930651-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06930651)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Phase I/II Study of CAR.70
 -Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Rece
 ptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy
  for the Management of Relapsed/Refractory Myeloid Malignancies\nEstimated
  primary completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06930651
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136650-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06136650)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study of Opevesostat (MK-568
 4) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic C
 astration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)\nEs
 timated primary completion: 10 May 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06136650
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643103-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07643103)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Immuno-Targeted Therapy Plus L
 ow-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospe
 ctive Umbrella Trial\nEstimated primary completion: 31 May 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07643103
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560449-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07560449)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: QLS4131 Combination Therapy in
  Malignant Plasma Cell Neoplasms\nEstimated primary completion: June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07560449
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03617731-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03617731)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Trial on the Effect of Isatuxi
 mab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidom
 ide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)\nEstim
 ated primary completion: June 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03617731
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02735707-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT02735707)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Randomized\, Embedded\, Multif
 actorial Adaptive Platform Trial for Community- Acquired Pneumonia\nEstima
 ted primary completion: June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT02735707
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877519-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dexamethasone: Phase na readout est. (NCT07877519)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Conscious Sedation Versus Gen
 eral Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial Fibrillatio
 n\nEstimated primary completion: June 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07877519
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891039-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07891039)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: ESP Blocks in Breast Free Flap
 s\nEstimated primary completion: 30 June 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07891039
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04847453-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT04847453)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Venetoclax\, MLN9708 (Ixazomib
  Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Li
 ght Chain Amyloidosis\nEstimated primary completion: 30 June 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04847453
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04546399-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04546399)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study to Compare Blinatumoma
 b Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Re
 lapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)\nEstimated primary compl
 etion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04546399
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839195-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07839195)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Effect of Post-Radiofrequency 
 Corticosteroid Injection on the Incidence of Post-Neurotomy Neuritis\nEsti
 mated primary completion: July 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07839195
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06905509-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06905509)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Epcoritamab Plus Standard of C
 are Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transpla
 nt for the Treatment of Relapsed or Refractory Large B-cell Lymphoma\nEsti
 mated primary completion: 1 July 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06905509
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05986318-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05986318)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Reducing Respiratory Symptoms 
 of Pulmonary Irradiation in Interstitial Lung Disease\nEstimated primary c
 ompletion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05986318
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789303-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05789303)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Study of Belantamab Mafodotin 
 With Carfilzomib\, Pomalidomide\, and Dexamethasone in Relapsed Multiple M
 yeloma\nEstimated primary completion: 1 July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05789303
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04530565-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04530565)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Testing the Use of Steroids an
 d Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly D
 iagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults\nEstimate
 d primary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04530565
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05292664-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280702
DTEND;VALUE=DATE:20280703
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT05292664)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Venetoclax Basket Trial for Hi
 gh Risk Hematologic Malignancies\nEstimated primary completion: 2 July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05292664
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07698080-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280703
DTEND;VALUE=DATE:20280704
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07698080)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Dexamethasone\, Intravenous In
 jection of Human Immunoglobulin\, and Increased Infusion of Mononuclear Ce
 lls to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic St
 em Cell Transplantation\nEstimated primary completion: 3 July 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07698080
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03643276-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03643276)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Treatment Protocol for Childre
 n and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017\n
 Estimated primary completion: 14 July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03643276
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583617-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT05583617)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study Evaluating the Safet
 y and Efficacy of Multiple Treatments in Participants With Multiple Myelom
 a\nEstimated primary completion: 31 July 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05583617
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04488081-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04488081)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: I-SPY COVID-19 TRIAL: An Adapt
 ive Platform Trial for Critically Ill Patients\nEstimated primary completi
 on: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dex
 amethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04488081
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05434689-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT05434689)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: COMbination Regimens in MM P
 ost AHCT to elimiNate MRD Utilizing IbERdomide\nEstimated primary completi
 on: August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexa
 methasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05434689
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06121843-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT06121843)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: A Study to Evaluate the Safety
 \, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-98639
 3) in Novel Combinations in Participants With Relapsed and/or Refractory M
 ultiple Myeloma\nEstimated primary completion: 1 August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06121843
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714839-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280803
DTEND;VALUE=DATE:20280804
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT05714839)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study to Investigate the S
 afety and Efficacy of Belantamab for the Treatment of Multiple Myeloma Whe
 n Used as Monotherapy and in Combination Treatments\nEstimated primary com
 pletion: 3 August 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05714839
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455396-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280814
DTEND;VALUE=DATE:20280815
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07455396)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Pediatric Asthma Trial of Cort
 icosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylpred
 nisolone for Pediatric Critical Asthma\nEstimated primary completion: 14 A
 ugust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexametha
 sone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07455396
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06305754-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06305754)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Sacituzumab Tirumotecan (MK-28
 70) Versus Pemetrexed and Carboplatin Combination Therapy in Participants 
 With Epidermal Growth Factor (EGFR)-Mutated\, Advanced Nonsquamous Non-sma
 ll Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kin
 ase Inhibitors (MK-2870-009)\nEstimated primary completion: 17 August 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06305754
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791264-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280828
DTEND;VALUE=DATE:20280829
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07791264)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: FPS-ZM1 With or Without Dexame
 thasone for Controlling Post Operative Cerebral Edema in Patients With Gli
 oblastoma\nEstimated primary completion: 28 August 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07791264
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07870447-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07870447)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Preoperative Celecoxib and A
 cetaminophen Versus Acetaminophen Alone for Pain Control After Pediatric A
 denotonsillectomy\nEstimated primary completion: 30 August 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07870447
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07588698-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07588698)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Epcoritamab in Combination Wit
 h R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma\nEstimated prim
 ary completion: 31 August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07588698
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674576-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07674576)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Efficacy of Intravenous Dexame
 thasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocain
 e in Knee Arthroscopy\nEstimated primary completion: 31 August 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07674576
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159620-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07159620)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Venetoclax Combined With Azaci
 tidine\, Chidamide\, Vindesine\, and Dexamethasone in Newly Diagnosed ETP-
 ALL Like Patients\nEstimated primary completion: 1 September 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07159620
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665762-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07665762)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Liposomal Bupivacaine Plus Pla
 in Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supracla
 vicular Brachial Plexus Block in Patients With Risk Factors for Severe Acu
 te Postoperative Pain\nEstimated primary completion: 1 September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07665762
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07344246-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Dexamethasone: Phase na readout est. (NCT07344246)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Efficacy and Safety of Intrav
 enous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zost
 er Pain\nEstimated primary completion: 1 September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07344246
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06968507-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280910
DTEND;VALUE=DATE:20280911
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT06968507)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Comparison of the Effectivenes
 s of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnose
 d With Sudden Sensorineural Hearing Loss\nEstimated primary completion: 10
  September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexa
 methasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06968507
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: GMMG-HD10 / DSMM-XX / 64007957
 MMY2003\, MajesTEC-5\nEstimated primary completion: 15 September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05695508
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185373-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT07185373)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: Orelabrutinib Combined With 
 Teniposide\, Rituximab and Methotrexate for Newly Diagnosed PCNSL\nEstimat
 ed primary completion: 30 September 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07185373
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04381936-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04381936)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Randomised Evaluation of COVID
 -19 Therapy\nEstimated primary completion: 30 September 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04381936
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06722118-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06722118)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Corticosteroids Before Extubat
 ion in Pediatric Intensive Care Unit\nEstimated primary completion: Octobe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 22118
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06635629-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06635629)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Desmopressin Stimulation Test 
 Performance in ACTH-Dependent Cushing Syndrome\nEstimated primary completi
 on: 1 October 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 examethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06635629
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05977998-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05977998)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Phase II Study of Perioperat
 ive Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis 
 or Positive Cytology\nEstimated primary completion: 31 October 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05977998
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00501826-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT00501826)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Combination Chemotherapy and N
 elarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or
  Lymphoblastic Lymphoma\nEstimated primary completion: 31 October 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT00501826
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528444-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06528444)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Clinical Trial Evaluating the 
 Efficacy and Safety of Dexamethasone Compared to Placebo in Patients With 
 Severe Influenza\nEstimated primary completion: 31 October 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06528444
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923643-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Dexamethasone: Phase na readout est. (NCT07923643)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Effect of Pectoral Nerve Bloc
 k (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Reco
 very and Chronic Post-Mastectomy Pain\nEstimated primary completion: Novem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethaso
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7923643
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07786051-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07786051)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: DiEtary Mimicry by Glucocortic
 oid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Effic
 acy and Response (DEMETER Trial)\nEstimated primary completion: 1 November
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0778
 6051
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02877303-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT02877303)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Blinatumomab\, Inotuzumab Ozog
 amicin\, and Combination Chemotherapy as Frontline Therapy in Treating Pat
 ients With B Acute Lymphoblastic Leukemia\nEstimated primary completion: 1
  November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexam
 ethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT02877303
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669989-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05669989)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: International Treatment-extens
 ion Study in Adult Participants With Multiple Myeloma and Who Have Derived
  Clinical Benefit From Isatuximab\nEstimated primary completion: 30 Novemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethason
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 669989
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136624-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06136624)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Study of Opevesostat (MK-5684)
  Versus Alternative NHA in mCRPC (MK-5684-003)\nEstimated primary completi
 on: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06136624
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555938-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07555938)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Cevostamab in Combination With
  Pomalidomide and Dexamethasone Versus Standard of Care in Participants Wi
 th Previously Treated Multiple Myeloma\nEstimated primary completion: 30 N
 ovember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamet
 hasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07555938
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832110-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07832110)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: The Effect of Dexamethasone 
 on Short Term Patient Response: IV vs Oral Administration\nEstimated prima
 ry completion: December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07832110
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848687-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT05848687)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: TINI 2: Total Therapy for In
 fants With Acute Lymphoblastic Leukemia II\nEstimated primary completion: 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexame
 thasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05848687
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561854-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06561854)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Study Comparing Therapy for Ad
 vanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
 \nEstimated primary completion: December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06561854
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06216158-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06216158)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Iberdomide vs. Iberdomide Plus
  Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myel
 oma\nEstimated primary completion: December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06216158
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04910568-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT04910568)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: A Study Evaluating the Safety\
 , Pharmacokinetics\, and Activity of Cevostamab in Participants With Relap
 sed or Refractory Multiple Myeloma\nEstimated primary completion: 21 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethaso
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4910568
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315373-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07315373)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Optimal Dose of Zanubrutinib t
 o Treat Adult Immune Thrombocytopenia\nEstimated primary completion: 30 De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexameth
 asone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07315373
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922501-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05922501)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Isatuximab\, Bela Maf\, Pom\, 
 and Dex in Relapsed/Refractory Multiple Myeloma\nEstimated primary complet
 ion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05922501
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06160791-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06160791)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Ruxolitinib With De-Intensifie
 d HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)\nEs
 timated primary completion: 31 December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06160791
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301138-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07301138)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: BEBT-908 Plus Chemotherapy Tre
 atment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic 
 Leukemia Patients\nEstimated primary completion: 31 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07301138
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317662-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06317662)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Testing the Addition of the An
 ti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumoma
 b to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT
 2A-rearranged or KMT2A-non-rearranged Leukemia\nEstimated primary completi
 on: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06317662
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04474223-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04474223)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Surveillance and Treatment to 
 Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)\n
 Estimated primary completion: 31 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04474223
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709884-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07709884)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: A Single-center\, Prospective\
 , Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Mul
 tiple Myeloma Patients With t(11\;14) Suitable for Transplantation Using t
 he SonKRd Regimen\nEstimated primary completion: 31 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07709884
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06984822-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dexamethasone: Phase na readout est. (NCT06984822)
DESCRIPTION:Dexamethasone\, phase na.\nStudy: Evaluation of Serum- and OCT 
 Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Im
 plant\nEstimated primary completion: 31 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06984822
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03661645-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT03661645)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Post-operative Methylprednisol
 one Taper Course for Orthopedic Surgery\nEstimated primary completion: Jan
 uary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethas
 one#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03661645
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085728-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07085728)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Testing the Investigational Ag
 ent Combination of Daratumumab\, Bortezomib\, and Dexamethasone Compared t
 o the Usual Treatment of Cyclophosphamide\, Bortezomib\, and Dexamethasone
  in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure\nEstimat
 ed primary completion: 11 January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07085728
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07764978)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Study of AZD0120 in Newly Diag
 nosed Multiple Myeloma Ineligible for ASCT\nEstimated primary completion: 
 11 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexa
 methasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07764978
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353386-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06353386)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Substudy 01A: Safety and Eff
 icacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat
  Alone in Participants With Metastatic Castration-resistant Prostate Cance
 r (mCRPC) (MK-5684-01A)\nEstimated primary completion: 15 January 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06353386
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07858773-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290130
DTEND;VALUE=DATE:20290131
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07858773)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Prevent Wheeze Trial\nEstimate
 d primary completion: 30 January 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07858773
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438043-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT05438043)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study of Daratumumab\nEstima
 ted primary completion: 31 January 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05438043
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348393-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07348393)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Phase 2\, Single Arm Multice
 nter\, Study Testing Mezigdomide\, Carfilzomib\, and Dexamethasone (480Kd)
  in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)\nEsti
 mated primary completion: February 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07348393
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06968559-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290207
DTEND;VALUE=DATE:20290208
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06968559)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Effect of Early Dexamethasone 
 on Major Complications and All-cause Mortality in Severe Burns\nEstimated 
 primary completion: 7 February 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06968559
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04923893-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04923893)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study of Bortezomib\, Lenali
 domide and Dexamethasone (VRd) Followed by Cilta-cel\, a CAR-T Therapy Dir
 ected Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (
 Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom
  ASCT is Not Planned as Initial Therapy\nEstimated primary completion: 14 
 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexame
 thasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04923893
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614360-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07614360)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Study of Alternative and Appro
 ved Dosing Regimens of Belantamab Mafodotin\, Bortezomib\, and Dexamethaso
 ne (BVd) in Participants With Relapsed/Refractory Multiple Myeloma\nEstima
 ted primary completion: 28 February 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07614360
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05896228-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05896228)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Iberdomide\, Daratumumab\, Car
 filzomib\, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refracto
 ry Multiple Myeloma\nEstimated primary completion: 1 March 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05896228
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918431-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06918431)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Asparaginase Erwinia Chrysanth
 emi With Chemotherapy for the Treatment of High-Risk Adults With Newly Dia
 gnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma\nEstimated p
 rimary completion: 30 March 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06918431
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608731-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07608731)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Golcadomide With Pemetrexed\, 
 Rituximab\, and Dexamethasone for Relapsed and Refractory CNS Lymphomas\nE
 stimated primary completion: April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07608731
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04822337-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT04822337)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Study of Carfilzomib\, Lenal
 idomide\, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma\nEsti
 mated primary completion: April 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04822337
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05658640-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT05658640)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: HEM iSMART-D: Trametinib + D
 examethasone + Chemotherapy in Children With Relapsed or Refractory Hemato
 logical Malignancies\nEstimated primary completion: 1 April 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05658640
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876128-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07876128)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Clinical Trial of MK-2750 
 in Participants With Advanced Solid Tumors (MK-2750-002)\nEstimated primar
 y completion: 12 April 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07876128
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825064-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290413
DTEND;VALUE=DATE:20290414
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07825064)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Cevostamab in Combination With
  Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy i
 n Participants With Previously Treated Multiple Myeloma\nEstimated primary
  completion: 13 April 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07825064
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824467-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06824467)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Evaluate the Effica
 cy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment V
 ersus Standard of Care in Participants With Platinum-sensitive Recurrent O
 varian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)\nEstimated pri
 mary completion: 27 April 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06824467
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891923-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290505
DTEND;VALUE=DATE:20290506
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07891923)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Less Doses of Daratumumab Are 
 Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma\nEstimate
 d primary completion: 5 May 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07891923
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Compare Linvoseltam
 ab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With St
 andard-of-Care Combination Regimens in Adult Participants With Relapsed/Re
 fractory Multiple Myeloma (RRMM)\nEstimated primary completion: 21 May 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07222761
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04729114-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT04729114)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: A Safety and Dose-finding Stud
 y of PRL-02 Depot in Men With Advanced Prostate Cancer\nEstimated primary 
 completion: 31 May 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04729114
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014462-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07014462)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: A Phase 1B Investigator Initia
 ted Study of Safety and Tolerability of Dexamethasone (D) in Combination W
 ith Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute
  Myeloid Leukemia (AML): DLIT-AML\nEstimated primary completion: June 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07014462
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06190158-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT06190158)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Subclinical Primary Aldosteron
 ism in Diabetes At-Risk for Kidney Disease\nEstimated primary completion: 
 31 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamet
 hasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06190158
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03948035-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03948035)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Elotuzumab in Combination With
  Carfilzomib\, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM\nEs
 timated primary completion: August 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03948035
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07777276-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290817
DTEND;VALUE=DATE:20290818
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07777276)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Sleep Quality - Comparing the 
 Effect of Ondansetron or Dexamethasone Given as Routine Prophylaxis Intrao
 peratively to Prevent Post Operative Nausea and Vomiting (SCORPION)\nEstim
 ated primary completion: 17 August 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07777276
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576660-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07576660)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Dexamethasone Treatment for Se
 psis-associated Acute Respiratory Distress Syndrome: a Multicenter\, Rando
 mised\, Double-blinded\, Controlled Trial\nEstimated primary completion: 3
 0 September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dex
 amethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07576660
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07861776-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07861776)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Efficacy of Short Course of In
 travenous Dexamethasone and Intravenous Immunoglobulin Therapy in Infectio
 n-Related Secondary Hemophagocytic Lymphohistiocytosis (isHLH)\nEstimated 
 primary completion: 30 September 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07861776
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772024-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07772024)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Inobrodib\, Pomalidomide and D
 examethasone Versus Standard Available Therapy in Relapsed or Refractory M
 ultiple Myeloma\nEstimated primary completion: November 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07772024
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05527340-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05527340)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Iberdomide-dexamethasone Alone
  or in Combination With Standard MM Treatment Regimens in Transplant Ineli
 gible Newly Diagnosed Patients.\nEstimated primary completion: December 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0552734
 0
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762170-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07762170)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Success Rates and Safety of St
 eroid Injections in Managing Spinal and Sacro-Iliac Pain (CORTisone Inject
 ion Spine Study)\nEstimated primary completion: December 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07762170
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04240054-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04240054)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Bortezomib\, Isatuximab\, Cycl
 ophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple M
 yeloma Patients With Renal Insufficiency\nEstimated primary completion: 1 
 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexame
 thasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04240054
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07096778-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07096778)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Inobrodib\, Pomalidomide and D
 examethasone in Relapsed or Refractory Multiple Myeloma\nEstimated primary
  completion: 1 December 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07096778
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513129-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07513129)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: Venetoclax\, Dexamethasone\, B
 ortezomib\, and Daratumumab For The Treatment Of Adolescent And Young Adul
 ts With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-c
 ell Acute Lymphoblastic Lymphoma\nEstimated primary completion: 31 Decembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 13129
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06518551-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT06518551)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: ELEVATE-MM: Elotuzumab\, Iberd
 omide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refrac
 tory Multiple Myeloma\nEstimated primary completion: 31 December 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06518551
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03937635-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03937635)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Lenalidomide\, and Dexamethaso
 ne With or Without Daratumumab in Treating Patients With High-Risk Smolder
 ing Myeloma\nEstimated primary completion: 31 December 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03937635
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04998786-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT04998786)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Multi-center Open-label Phas
 e 2 Study of Ixazomib\, Iberdomide and Dexamethasone in Elderly Patients W
 ith Multiple Myeloma at First Relapse."\nEstimated primary completion: 1 J
 anuary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexameth
 asone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04998786
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06336395-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06336395)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Ma-Spore ALL 2020 Study\nEstim
 ated primary completion: March 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06336395
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284758-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07284758)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study to Evaluate the Effica
 cy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory
  Multiple Myeloma\nEstimated primary completion: March 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07284758
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04043494-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300422
DTEND;VALUE=DATE:20300423
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04043494)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: International Cooperative Trea
 tment Protocol for Children and Adolescents With Lymphoblastic Lymphoma\nE
 stimated primary completion: 22 April 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04043494
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770698-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07770698)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study of Sonrotoclax (BGB-
 11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and 
 B-cell Acute Lymphoblastic Leukemia\nEstimated primary completion: 30 Apri
 l 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 70698
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07084441-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT07084441)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Comparison of Outcomes of Mana
 gement of Bowel Obstruction\nEstimated primary completion: June 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07084441
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002216-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300715
DTEND;VALUE=DATE:20300716
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07002216)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: BrECADD Therapy in Stage 2 B-I
 V Hodgkin Lymphoma\nEstimated primary completion: 15 July 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07002216
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06022939-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300729
DTEND;VALUE=DATE:20300730
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06022939)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Comparing Dara-VCD Chemotherap
 y Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who 
 Have Newly Diagnosed AL Amyloidosis\nEstimated primary completion: 29 July
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0602
 2939
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227584-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07227584)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: ALL Backbone in AYAs\nEstimate
 d primary completion: 31 July 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07227584
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543458-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07543458)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Therapeutics for Moderate and 
 Severe Dengue\nEstimated primary completion: 31 July 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07543458
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04300556-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300808
DTEND;VALUE=DATE:20300809
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT04300556)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study to Evaluate the Safe
 ty\, Tolerability\, and Efficacy of MORAb-202 (Herein Referred to as Farle
 tuzumab Ecteribulin)\, a Folate Receptor Alpha (FRα)-Targeting Antibody-d
 rug Conjugate (ADC) in Participants With Selected Tumor Types\nEstimated p
 rimary completion: 8 August 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04300556
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227311-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07227311)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study to Evaluate the Effica
 cy and Safety of Belantamab Mafodotin in Combination With Standard of Care
  in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)\nEstimat
 ed primary completion: 30 August 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07227311
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of Different Sequences
  of Cilta-cel\, Talquetamab in Combination With Daratumumab and Teclistama
 b in Combination With Daratumumab Following Induction With Daratumumab\, B
 ortezomib\, Lenalidomide and Dexamethasone in Participants With Standard-r
 isk Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 2 Sept
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexametha
 sone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06577025
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997081-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06997081)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: ERd Combination Treatment in N
 ewly Diagnosed Multiple Myeloma (ADVANCE 2.0)\nEstimated primary completio
 n: 30 September 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06997081
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07584525-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07584525)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Dexamethasone in Tick-borne En
 cephalitis\nEstimated primary completion: 30 September 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07584525
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07856069-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07856069)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Arsenic Trioxide Combined With
  Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastom
 a\nEstimated primary completion: October 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07856069
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04270409-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20301014
DTEND;VALUE=DATE:20301015
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04270409)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Isatuximab in Combination With
  Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma\n
 Estimated primary completion: 14 October 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04270409
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953960-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06953960)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study to Assess Adverse Ev
 ents and Change in Disease Activity of Oral Surzetoclax Alone or in Combin
 ation With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participan
 ts With Multiple Myeloma (MM)\nEstimated primary completion: December 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06953960
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247097-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07247097)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: ELDORADO: Elranatamab Versus D
 aratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ine
 ligible/Deferred Multiple Myeloma\nEstimated primary completion: 1 Decembe
 r 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 47097
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828054-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20301220
DTEND;VALUE=DATE:20301221
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07828054)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Premedication With Dexamethaso
 ne for Preventing Interstitial Lung Disease in Patients With Breast Cancer
  Treated With Trastuzumab Deruxtecan\nEstimated primary completion: 20 Dec
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexametha
 sone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07828054
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06187441-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06187441)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: FeAsiBility of a Treatment Fre
 e Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalid
 omide-dexamethasone (HOVON174MM)\nEstimated primary completion: January 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0618744
 1
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: European Proof-of-Concept Th
 erapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refra
 ctory Tumors\nEstimated primary completion: February 2031. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03418038-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310222
DTEND;VALUE=DATE:20310223
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT03418038)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Ascorbic Acid and Chemotherapy
  for the Treatment of Relapsed or Refractory Lymphoma\, CCUS\, and Chronic
  Myelomonocytic Leukemia\nEstimated primary completion: 22 February 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03418038
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616597-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310330
DTEND;VALUE=DATE:20310331
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06616597)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Trial Targeting Gut Bacterial 
 Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Pa
 tients With Metastatic Prostate Cancer\nEstimated primary completion: 30 M
 arch 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethas
 one#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06616597
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06785415-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310401
DTEND;VALUE=DATE:20310402
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06785415)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Elotuzumab\, Daratumumab\, I
 berdomide\, and Dexamethasone for the Treatment of Relapsed Multiple Myelo
 ma\nEstimated primary completion: 1 April 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06785415
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636564-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310416
DTEND;VALUE=DATE:20310417
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07636564)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Testing Blinatumomab With or W
 ithout Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With
  a Genetic Change Requiring More Treatment\nEstimated primary completion: 
 16 April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexame
 thasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07636564
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679101-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310428
DTEND;VALUE=DATE:20310429
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06679101)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study of Belantamab Mafodoti
 n Administered in Combination With Lenalidomide and Dexamethasone (BRd) Ve
 rsus Daratumumab\, Lenalidomide\, and Dexamethasone (DRd) in Participants 
 With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autolo
 gous Stem Cell Transplantation (TI-NDMM)\nEstimated primary completion: 28
  April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexameth
 asone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06679101
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03314181-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT03314181)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study of Combination Therapy
  With Venetoclax\, Daratumumab and Dexamethasone (With and Without Bortezo
 mib) in Participants With Relapsed or Refractory Multiple Myeloma\nEstimat
 ed primary completion: May 2031. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03314181
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05991388-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310501
DTEND;VALUE=DATE:20310502
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT05991388)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: A Global Study of Novel Agen
 ts in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin
  Lymphoma\nEstimated primary completion: 1 May 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05991388
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05561387-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310530
DTEND;VALUE=DATE:20310531
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT05561387)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Comparing Combinations of Drug
 s to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transp
 lant is Not a Medically Suitable Treatment\nEstimated primary completion: 
 30 May 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexameth
 asone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05561387
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04513639-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT04513639)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: The Relapse from MRD Negativ
 ity As Indication for Treatment (REMNANT) Study\nEstimated primary complet
 ion: 1 June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dex
 amethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04513639
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07870278-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310705
DTEND;VALUE=DATE:20310706
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07870278)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: A Clinical Trial of MK-6255 to
  Treat Endometrial and Ovarian Cancer (MK-6255-001)\nEstimated primary com
 pletion: 5 July 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07870278
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609706-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310822
DTEND;VALUE=DATE:20310823
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT07609706)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: A Study of the Combination of 
 Belantamab Mafodotin\, Bortezomib\, and Dexamethasone (BVd) in Participant
 s With Multiple Myeloma and Moderate Hepatic Impairment\nEstimated primary
  completion: 22 August 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07609706
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07785609-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07785609)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Clinical Trial of MK-2010 Wi
 th Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK
 -2010)\nEstimated primary completion: 30 September 2031. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07785609
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175415-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20311001
DTEND;VALUE=DATE:20311002
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07175415)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: HEM-iSMART E: Capivasertib +
  Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refract
 ory Hematological Malignancies\nEstimated primary completion: 1 October 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0717541
 5
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285239-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07285239)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Belantamab Mafodotin or Daratu
 mumab With Bortezomib\, Lenalidomide and Dexamethasone for Newly Diagnosed
  Multiple Myeloma\nEstimated primary completion: November 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07285239
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901868-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07901868)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Elranatamab With Mezigdomide a
 nd Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma\nEs
 timated primary completion: December 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07901868
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01553214-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20320101
DTEND;VALUE=DATE:20320102
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT01553214)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Improving White Blood Cell Col
 lection From Healthy Donors\nEstimated primary completion: 1 January 2032.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT01553214
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06182774-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06182774)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Fixed Duration vs Continuous A
 nti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Ne
 wly-Diagnosed Multiple Myeloma\nEstimated primary completion: 31 January 2
 032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT061827
 74
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05745714-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT05745714)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: HEM-iSMART-C: Ruxolitinib + 
 Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric 
 Patients With Relapsed or Refractory Hematological Malignancies\nEstimated
  primary completion: 1 February 2032. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05745714
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05751044-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT05751044)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: HEM-iSMART-B: Dasatinib + Ve
 netoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Pa
 tients With Relapsed or Refractory Hematological Malignancies\nEstimated p
 rimary completion: 1 February 2032. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05751044
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788912-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20320206
DTEND;VALUE=DATE:20320207
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06788912)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Pembrolizumab (MK-3475) Plus I
 nvestigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK
 -3475-01E/KEYMAKER-U01)\nEstimated primary completion: 6 February 2032. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06788912
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03959085-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03959085)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Inotuzumab Ozogamicin and Post
 -Induction Chemotherapy in Treating Patients With High-Risk B-ALL\, Mixed 
 Phenotype Acute Leukemia\, and B-LLy\nEstimated primary completion: 31 Mar
 ch 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethason
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 959085
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908524-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20320629
DTEND;VALUE=DATE:20320630
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07908524)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: MK-2870-U01 Substudy 1: A Cl
 inical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-
 01A)\nEstimated primary completion: 29 June 2032. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07908524
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04507412-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20320731
DTEND;VALUE=DATE:20320801
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT04507412)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Intravenous Dexamethasone Admi
 nistration in Patients Undergoing Total Shoulder Arthroplasty\nEstimated p
 rimary completion: 31 July 2032. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04507412
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06762769-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20321101
DTEND;VALUE=DATE:20321102
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06762769)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Isatuximab and Iberdomide as I
 mmunotherapy for High Risk in Smouldering Myeloma\nEstimated primary compl
 etion: 1 November 2032. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06762769
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605416-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20321106
DTEND;VALUE=DATE:20321107
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07605416)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Testing an Experimental Approa
 ch to Treat Patients With Plasma Cell Leukemia\, The QUANTUM Trial\nEstima
 ted primary completion: 6 November 2032. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07605416
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224672-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20330112
DTEND;VALUE=DATE:20330113
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07224672)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Study to Evaluate the Effica
 cy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide
 \, Bortezomib\, and Dexamethasone in Adult Participants With Newly Diagnos
 ed Amyloid Light Chain (AL) Amyloidosis\nEstimated primary completion: 12 
 January 2033. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamet
 hasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07224672
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748689-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07748689)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Comparing Lower Versus Standar
 d Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Rel
 apsed or Refractory Multiple Myeloma.\nEstimated primary completion: March
  2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0774
 8689
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05145400-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20330528
DTEND;VALUE=DATE:20330529
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT05145400)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Isa-Rd for Frail and/or Much O
 lder Patients With Newly Diagnosed Multiple Myeloma\nEstimated primary com
 pletion: 28 May 2033. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05145400
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257083-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT05257083)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study of Daratumumab\, Borte
 zomib\, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene A
 utoleucel Versus Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone
  (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants
  With Newly Diagnosed Multiple Myeloma\nEstimated primary completion: June
  2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0525
 7083
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04307576-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04307576)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Treatment Study Protocol for
  Participants 0-45 Years With Acute Lymphoblastic Leukaemia\nEstimated pri
 mary completion: June 2033. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04307576
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07768943-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07768943)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: GELAD-Based Response-Adapted T
 reatment for Early-Stage Extranodal NK/T-Cell Lymphoma\nEstimated primary 
 completion: 30 June 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07768943
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887984-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT07887984)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: Comparing Bispecific Antibod
 y Treatment to Autologous Stem Cell Transplant for Newly Diagnosed\, Stand
 ard Risk Multiple Myeloma\nEstimated primary completion: 1 August 2033. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07887984
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05259839-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:Dexamethasone: Phase 1 readout est. (NCT05259839)
DESCRIPTION:Dexamethasone\, phase 1.\nStudy: A Study to Assess Adverse Even
 ts and Change in Disease Activity of Intravenously (IV) Infused Etentamig 
 (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of A
 dult Participants With Relapsed/Refractory Multiple Myeloma\nEstimated pri
 mary completion: September 2033. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05259839
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387926-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20330919
DTEND;VALUE=DATE:20330920
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07387926)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Safety and Efficacy of Ascim
 inib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadel
 phia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL
 )\nEstimated primary completion: 19 September 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07387926
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624513-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20331001
DTEND;VALUE=DATE:20331002
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07624513)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: D2 - Isa-Iber-VD Induction\, F
 ollowed by Risk & Response Adapted Consolidation & Maintenance\, in Transp
 lant-Eligible NDMM\nEstimated primary completion: 1 October 2033. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07624513
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570173-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20331018
DTEND;VALUE=DATE:20331019
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT07570173)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: A Clinical Trial of MK-1045 
 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)\nEstimate
 d primary completion: 18 October 2033. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07570173
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709000-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20331116
DTEND;VALUE=DATE:20331117
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT07709000)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: A Clinical Trial of MK-1045 in
  People With B-cell Cancer (MK-1045-006)\nEstimated primary completion: 16
  November 2033. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexam
 ethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07709000
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06099366-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT06099366)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Treatment of Newly Diagnosed S
 tandard Risk Acute Lymphoblastic Leukemia in Children\nEstimated primary c
 ompletion: 31 December 2033. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06099366
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02106988-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20340131
DTEND;VALUE=DATE:20340201
SUMMARY:Dexamethasone: Phase 2 readout est. (NCT02106988)
DESCRIPTION:Dexamethasone\, phase 2.\nStudy: Concurrent Chemotherapy and Ra
 diation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma\nEstimated prim
 ary completion: 31 January 2034. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT02106988
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06289673-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20340531
DTEND;VALUE=DATE:20340601
SUMMARY:Dexamethasone: Phase 4 readout est. (NCT06289673)
DESCRIPTION:Dexamethasone\, phase 4.\nStudy: Identification of Necessary In
 formation for Treatment Induction in Newly Diagnosed Acute Lymphoblastic L
 eukemia/Lymphoma\nEstimated primary completion: May 2034. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06289673
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072585-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20350901
DTEND;VALUE=DATE:20350902
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT07072585)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: Testing the Addition of Dara
 tumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell 
 Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)\nE
 stimated primary completion: 1 September 2035. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07072585
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: A Study to Assess Change in 
 Disease Activity and Adverse Events (AE)s in Adult Participants With Multi
 ple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intraveno
 usly (IV)/Subcutaneously (SC) Alone or in Combinations\nEstimated primary 
 completion: December 2035. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918002-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20360531
DTEND;VALUE=DATE:20360601
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06918002)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Elranatamab/Lenalidomide Conso
 lidation and/or Elranatamab Maintenance Versus Standard of Care After D-VR
 d Induction in Transplant-eligible NDMM Patients\nEstimated primary comple
 tion: May 2036. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexam
 ethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06918002
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600151-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Dexamethasone: Phase 1/2 readout est. (NCT07600151)
DESCRIPTION:Dexamethasone\, phase 1/2.\nStudy: Etenta-Isa-VRd in Newly Diag
 nosed High-Risk Multiple Myeloma\nEstimated primary completion: 30 Septemb
 er 2036. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethason
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 600151
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06932562-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06932562)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Learn How Safe and 
 How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patie
 nts With Multiple Myeloma Who Are Not Eligible for Transplant\nEstimated p
 rimary completion: December 2036. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06932562
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903506-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20390331
DTEND;VALUE=DATE:20390401
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07903506)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: To Evaluate Safety and Efficac
 y of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in N
 ewly Diagnosed Multiple Myeloma\nEstimated primary completion: March 2039.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07903506
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887672-8936@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20420228
DTEND;VALUE=DATE:20420301
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07887672)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Trial to Evaluate Safety and
  Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Di
 agnosed Multiple Myeloma\nEstimated primary completion: February 2042. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07887672
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
